

RADIOTHERAPY: TECHNOLOGIES AND GLOBAL MARKETS



HLC176A
February 2015

Neha Maliwal
Project Analyst

ISBN: 1-62296-043-2



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	3
INTENDED AUDIENCE	3
RESEARCH METHODOLOGY	3
ANALYST'S CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	5
CHAPTER 2 EXECUTIVE SUMMARY	7
<i>SUMMARY TABLE RADIATION THERAPY MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE RADIATION THERAPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	8
CHAPTER 3 MARKET OVERVIEW	11
INTRODUCTION	11
INTRODUCTION TO CANCER	11
BENIGN TUMORS	12
MALIGNANT TUMORS	12
Malignant Tumor Categories	12
Carcinomas	12
Sarcomas	12
OTHER TYPES OF CANCER	12
<i>TABLE 1 CHARACTERISTICS OF BENIGN AND MALIGNANT TUMORS</i>	13
CAUSES OF CANCER	13
Internal Factors	13
External Factors	13
CANCER PROTECTIVE FACTORS AND RISK FACTORS	13
<i>TABLE 2 THE IMPACT OF CANCER PROTECTIVE FACTORS AND CANCER RISK FACTORS ON VARIOUS TYPES OF CANCERS</i>	14
INTRODUCTION TO RADIATION	14
<i>FIGURE 1 TYPES OF RADIATION</i>	14
NON-IONIZING RADIATION	15
IONIZING RADIATION	15
PARTICLE RADIATION	16
Electron Beams	16
Proton Beams	16
Neutron Beams	16
Carbon Ions	16
Alpha and Beta Particles	17
Photon Radiations	17
Gamma Rays	17
X-rays	17

TOPIC	PAGE NO.
HISTORY OF RADIATION THERAPY	17
The Discovery Period	17
Megavoltage Era (1946-1996)	18
Computer-assisted ERA (1996-2013)	19
MECHANISM OF ACTION	19
CELL GROWTH CYCLE	19
<i>FIGURE 2 CELL GROWTH CYCLE</i>	19
<i>TABLE 3 STEPS INVOLVED IN RADIATION THERAPY</i>	21
RISK MANAGEMENT AND QUALITY ASSURANCE IN RADIATION THERAPY	21
RADIATION THERAPY MARKET SEGMENTATION	22
<i>FIGURE 3 RADIATION THERAPY MARKET SEGMENTATION</i>	22
DRIVERS, RESTRAINTS, OPPORTUNITIES AND TRENDS	23
<i>FIGURE 4 DRIVERS, RESTRAINTS, OPPORTUNITIES AND TRENDS IN THE RADIATION THERAPY MARKET</i>	23
DRIVERS	23
Increasing Incidences of Cancer	23
High Incidence of Cancer in Aging Population	24
<i>FIGURE 5 GLOBAL AGING POPULATION (MILLIONS)</i>	24
<i>FIGURE 6 FACTORS RELATED TO AGING AND THE PROMOTION OF CANCER</i>	25
High Efficiency of Radiotherapy	25
Palliative Radiation Therapy	26
Government Funding	26
Advancement in Technology	26
Reimbursement Boosting Market Growth	27
RESTRAINTS	27
Capital Intensive	27
Lack of Trained Professionals	27
Limited Effectiveness against Metastatic Cancer	27
Side Effects Associated with Radiation Therapy	28
OPPORTUNITY	28
Developing Countries	28
Personalized Treatment	28
TRENDS	28
VMAT	29
Proton Therapy	29
Carbon Ions	29
THREAT	30
Recession Can Restrict the Growth of Radiation Therapy Market	30
MARKET SHARE ANALYSIS	30
<i>FIGURE 7 MARKET SHARE ANALYSIS OF THE RADIATION THERAPY MARKET, 2013 (%)</i>	30
VARIOUS CANCER TREATMENTS	31
<i>TABLE 4 ADVANTAGES AND DISADVANTAGES OF VARIOUS CANCER TREATMENTS</i>	31
STEREOTACTIC RADIOSURGERY (SRS) AND FRACTIONATED STEREOTACTIC RADIATION THERAPY	32
CHAPTER 4 RADIATION THERAPY MARKET BY PRODUCTS	34

TOPIC	PAGE NO.
<i>TABLE 5 COMPARISON OF EXTERNAL BEAM RADIATION THERAPY AND BRACHYTHERAPY</i>	34
EXTERNAL BEAM RADIATION THERAPY	34
TREATMENT PLANNING FOR EXTERNAL BEAM RADIATION	35
Dosing and Treatment with External Beam Radiation	35
<i>TABLE 6 EXTERNAL BEAM RADIATION THERAPY MARKET BY TYPE THROUGH 2019 (\$ MILLIONS)</i>	36
<i>TABLE 7 EXTERNAL BEAM RADIATION THERAPY BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	37
GAMMA KNIFE	37
MECHANISM OF ACTION	38
<i>TABLE 8 GAMMA KNIFE MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	39
LINEAR ACCELERATORS (LINACS)	39
Structure of Linear Accelerators	40
Electron Guns	40
The Buncher	40
The LINACS	41
Magnetrons	41
Klystrons	42
Beam Collimation and Monitoring	42
<i>TABLE 9 ELECTRON EMITTING HIGH ENERGY LINEAR ACCELERATORS BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	43
<i>TABLE 10 LINACS MARKET BY TECHNIQUES, THROUGH 2019 (\$ MILLIONS)</i>	43
TYPES OF LINACS BY TECHNIQUES	44
Three-dimensional Conformal Radiation Therapy (3D-CRT)	44
<i>TABLE 11 THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	44
Intensity-modulated Radiation Therapy (IMRT)	45
High Cost Restricts the Use	46
<i>TABLE 12 INTENSITY-MODULATED RADIATION THERAPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	46
Image-guided Radiation Therapy (IGRT)	47
<i>TABLE 13 IMAGE-GUIDED RADIATION THERAPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	47
Other LINACS	48
<i>TABLE 14 OTHER LINACS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	48
PARTICLE THERAPY	48
<i>TABLE 15 COMPARISON OF PROTON BEAM THERAPY AND CARBON ION THERAPY</i>	50
<i>TABLE 16 PARTICLE THERAPY SYSTEM BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	51
<i>TABLE 17 PARTICLE THERAPY SYSTEM MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	51
<i>TABLE 18 PROTON SYSTEMS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	52
Carbon Ions	52
<i>TABLE 19 CARBON ION THERAPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	52
BRACHYTHERAPY	53
<i>TABLE 20 COMMONLY USED RADIONUCLIDES (RADIATION SOURCES) FOR BRACHYTHERAPY</i>	54
<i>TABLE 21 ADVANTAGES AND DISADVANTAGES OF BRACHYTHERAPY</i>	54
<i>TABLE 22 VARIOUS TYPES OF BRACHYTHERAPY IMPLANTS</i>	55

TOPIC	PAGE NO.
TABLE 23 BRACHYTHERAPY TREATMENT DURATION	55
TABLE 24 BRACHYTHERAPY TREATMENT DOSE RATE	56
TABLE 25 BRACHYTHERAPY TREATMENT SOURCE LOADING	56
PDR BRACHYTHERAPY	56
TABLE 26 COMPARISON OF LOW DOSE AND HIGH DOSE RADIATION THERAPY	57
TABLE 27 GLOBAL BRACHYTHERAPY MARKET BY PRODUCT, THROUGH 2019 (\$ MILLIONS)	58
TABLE 28 GLOBAL BRACHYTHERAPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	58
LDR BRACHYTHERAPY MARKET	58
TABLE 29 GLOBAL LDR BRACHYTHERAPY MARKET BY PRODUCT, THROUGH 2019 (\$ MILLIONS)	59
TABLE 30 GLOBAL LDR BRACHYTHERAPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	59
LDR Brachytherapy Seeds	59
TABLE 31 MARKET FOR LDR BRACHYTHERAPY SEEDS BY REGION, THROUGH 2019 (\$ MILLIONS)	60
Brachytherapy Seeds Market by Type of Radioisotope	61
TABLE 32 GLOBAL BRACHYTHERAPY SEEDS MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	61
Iodine-125	62
TABLE 33 GLOBAL I-125 SEEDS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	62
Palladium-103	62
TABLE 34 GLOBAL PD-103 SEEDS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	62
Other Seeds	63
TABLE 35 GLOBAL OTHER LDR BRACHYTHERAPY SEEDS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	63
TABLE 36 LDR AFTERLOADER AND APPLICATOR MARKET BY GEOGRAPHY THROUGH 2019 (\$ MILLIONS)	63
HDR BRACHYTHERAPY MARKET	64
TABLE 37 HDR BRACHYTHERAPY MARKET BY PRODUCT, THROUGH 2019 (\$ MILLIONS)	65
TABLE 38 HDR BRACHYTHERAPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	65
HDR Brachytherapy Seed Market	66
TABLE 39 HDR SEEDS MARKET BY PRODUCT, THROUGH 2019 (\$ MILLIONS)	67
TABLE 40 HDR SEEDS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	67
Iridium-192 seeds	67
TABLE 41 IR-192 SEEDS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	68
Other HDR Seeds	68
TABLE 42 OTHER HDR SEEDS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	69
TABLE 43 HDR AFTERLOADER AND APPLICATOR MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	69
ELECTRONIC BRACHYTHERAPY	69
TABLE 44 COMPARISON BETWEEN RADIONUCLIDES AND ELECTRONIC BRACHYTHERAPY	71
TABLE 45 GLOBAL ELECTRONIC BRACHYTHERAPY MARKET BY GEOGRAPHY THROUGH 2019 (\$ MILLIONS)	71
THERAPEUTIC RADIOPHARMACEUTICALS BY TYPE	71
TABLE 46 ADVANTAGES AND DISADVANTAGES OF RADIOPHARMACEUTICALS	72

TOPIC	PAGE NO.
COMPARISON BETWEEN ALPHA AND BETA EMITTERS	72
<i>TABLE 47 COMPARISON OF ALPHA AND BETA PARTICLES</i>	73
SHORTAGE OF RADIONUCLIDES	73
CUMBERSOME REGULATORY REQUIREMENTS	73
<i>TABLE 48 MARKET FOR THERAPEUTIC RADIOPHARMACEUTICALS BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	74
<i>TABLE 49 SYSTEMIC RADIATION THERAPY BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	74
ALPHA EMITTERS	75
<i>TABLE 50 GLOBAL ALPHA EMITTER MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	75
<i>TABLE 51 GLOBAL ALPHA EMITTER MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	75
<i>TABLE 52 EXAMPLES OF ALPHA EMITTERS</i>	77
<i>TABLE 53 ADVANTAGES AND DISADVANTAGES OF ALPHA EMITTERS</i>	77
Radium-223	79
Mechanism of Action	79
BETA EMITTERS	80
<i>TABLE 54 GLOBAL BETA EMITTERS MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	80
<i>TABLE 55 ADVANTAGES AND DISADVANTAGES OF BETA EMITTERS</i>	81
<i>TABLE 56 MARKET FOR BETA EMITTERS BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	82
Iodine-131	83
<i>TABLE 57 GLOBAL IODINE-131 MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	83
Rhenium (Re-186)	84
<i>TABLE 58 GLOBAL RHENIUM-186 MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	84
Samarium (Sm-153)	84
<i>TABLE 59 GLOBAL SAMARIUM-153 MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	85
Yttrium-90 (Y-90)	86
<i>TABLE 60 GLOBAL YTTRIUM-90 MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	86
Lutetium-177 (Lu-177)	87
<i>TABLE 61 GLOBAL LUTETIUM-177 MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	87
Others	87
<i>TABLE 62 GLOBAL OTHER BETA EMITTERS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	87
ROUTE OF ADMINISTRATION	88
Introduction	88
Intravenous Administration	88
Inhalation Administration	88
Peroral Administration	89
Other Routes of Administration	89
<i>TABLE 63 OTHER ROUTES OF ADMINISTRATION</i>	89
PIPELINE PRODUCTS	89
<i>TABLE 64 PIPELINE PRODUCTS IN RADIOPHARMACEUTICALS</i>	90
CHAPTER 5 RADIATION THERAPY MARKET BY APPLICATION	93
EXTERNAL BEAM RADIATION THERAPY MARKET	93
<i>TABLE 65 EXTERNAL BEAM RADIATION THERAPY BY APPLICATION, THROUGH 2019 (\$ MILLIONS)</i>	93
PROSTATE CANCER	93

TOPIC	PAGE NO.
Life Expectancy	94
Overall Health Status	94
Tumor Characteristics	94
Stage I Prostate Cancer	94
Stage II Prostate Cancer	94
Stage III Prostate Cancer	95
Stage IV Prostate Cancer	95
Personal Preferences	96
Advantages of EBRT in Treating Prostate Cancer	97
Side Effects	97
Disadvantages	97
BREAST CANCER	97
LUNG CANCER	98
Types of Lung Cancer	99
Non-Small Cell Lung Cancer	99
Small Cell Lung Cancer	99
Lung Carcinoid Tumor	99
HEAD AND NECK CANCER	99
Conformal Radiation Therapy (CRT)	100
OTHER CANCERS	101
INTERNAL RADIATION THERAPY MARKET BY APPLICATION	101
<i>TABLE 66 INTERNAL BEAM RADIATION THERAPY BY APPLICATION THROUGH 2019 (\$ MILLIONS)</i>	101
PROSTATE CANCER	101
HEAD AND NECK CANCER	102
GYNECOLOGICAL CANCER	102
Vaginal Cancer	103
BREAST CANCER	103
CERVICAL CANCER	104
SYSTEMIC RADIATION THERAPY	104
<i>TABLE 67 SYSTEMIC RADIATION THERAPY BY APPLICATION, THROUGH 2019 (\$ MILLIONS)</i>	105
HYPERTHYROIDISM	105
BONE METASTASES	105
LYMPHOMA	106
ENDOCRINE TUMORS	107
CHAPTER 6 RADIATION THERAPY MARKET BY GEOGRAPHY	109
UNITED STATES	109
<i>TABLE 68 U.S. RADIATION THERAPY MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	109
<i>TABLE 69 U.S. INSTALLED BASE AND AGE</i>	109
<i>TABLE 70 NEW CANCER CASES AND ESTIMATED DEATHS IN THE YEAR 2014</i>	110
<i>TABLE 71 AGING U.S. POPULATION, 2000-2050</i>	110
EUROPE	111
<i>TABLE 72 EUROPEAN RADIATION THERAPY MARKET BY TYPE THROUGH 2019 (\$ MILLIONS)</i>	111
ASIA	112

TOPIC	PAGE NO.
<i>TABLE 73 ASIAN RADIATION THERAPY MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	112
JAPAN	113
<i>TABLE 74 COMPARISON OF INDIAN AND CHINESE RADIATION THERAPY MARKETS</i>	113
CHINA	113
INDIA	114
REST OF THE WORLD	114
<i>TABLE 75 REST OF THE WORLD RADIATION THERAPY MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	115
LATIN AMERICA	115
MIDDLE EAST	115
AFRICA	115
CHAPTER 7 COMPANY PROFILES	117
ACCURAY INCORPORATED	117
FINANCIALS	117
<i>TABLE 76 ACCURAY REVENUES AND R &D EXPENDITURES, 2011-2013 (\$ MILLIONS/%)</i>	117
PRODUCTS	117
<i>TABLE 77 ACCURAY PRODUCTS</i>	118
RECENT NEWS	118
<i>TABLE 78 ACCURAY RECENT NEWS</i>	118
ACTINIUM PHARMACEUTICALS INC.	119
AUSTRALIAN NUCLEAR ASSOCIATION AND TECHNOLOGY ORGANIZATION (ANSTO)	119
C. R. BARD INC.	120
FINANCIALS	120
<i>TABLE 79 C.R. BARD REVENUES AND R &D EXPENDITURES, 2011-2013 (\$ MILLIONS)</i>	120
PRODUCTS	121
ECKERT & ZIEGLER BEBIG S.A	121
FINANCIALS	121
<i>TABLE 80 ECKERT & ZIEGLER REVENUES AND R &D EXPENDITURES, 2011-2013 (\$ MILLIONS/%)</i>	122
PRODUCTS	122
RECENT NEWS	122
<i>TABLE 81 ECKERT & ZIEGLER RECENT NEWS</i>	122
ELEKTA	123
FINANCIALS	124
<i>TABLE 82 ELEKTA REVENUES AND R &D EXPENDITURES, 2011-2013 (\$ MILLIONS/%)</i>	124
PRODUCTS	124
RECENT NEWS	124
<i>TABLE 83 ELEKTA RECENT NEWS</i>	125
GE HEALTHCARE	126
GE HEALTHCARE LIFE SCIENCES	126
PRODUCTS	126
IBA MOLECULAR	127
NORDION INC.	127
NTP RADIOISOTOPES (PTY) LTD.	128

TOPIC	PAGE NO.
SIEMENS HEALTHCARE	128
FINANCIALS	129
<i>TABLE 84 SIEMENS REVENUES AND R & D EXPENDITURES, 2011-2013 (\$ MILLIONS/%)</i>	129
PRODUCTS	129
RECENT NEWS	129
<i>TABLE 85 SIEMENS RECENT NEWS</i>	129
VARIAN MEDICAL SYSTEMS	130
FINANCIALS	130
<i>TABLE 86 VARIAN REVENUES AND R & D EXPENDITURES, 2011-2013 (\$ MILLIONS/%)</i>	131
PRODUCTS	131
RECENT NEWS	131
<i>TABLE 87 VARIAN RECENT NEWS</i>	131
CHAPTER 8 APPENDIX A LIST OF HUMAN OF CARCINOGENIC AGENTS BY TYPE OF CANCER	135
<i>TABLE 88 LIST OF CARCINOGENIC AGENTS</i>	135
CHAPTER 9 APPENDIX B LIST OF ACRONYMS	137

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE RADIATION THERAPY MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	8
TABLE 1 CHARACTERISTICS OF BENIGN AND MALIGNANT TUMORS	13
TABLE 2 THE IMPACT OF CANCER PROTECTIVE FACTORS AND CANCER RISK FACTORS ON VARIOUS TYPES OF CANCERS	14
TABLE 3 STEPS INVOLVED IN RADIATION THERAPY	21
TABLE 4 ADVANTAGES AND DISADVANTAGES OF VARIOUS CANCER TREATMENTS	31
TABLE 5 COMPARISON OF EXTERNAL BEAM RADIATION THERAPY AND BRACHYTHERAPY	34
TABLE 6 EXTERNAL BEAM RADIATION THERAPY MARKET BY TYPE THROUGH 2019 (\$ MILLIONS)	36
TABLE 7 EXTERNAL BEAM RADIATION THERAPY BY REGION, THROUGH 2019 (\$ MILLIONS)	37
TABLE 8 GAMMA KNIFE MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	39
TABLE 9 ELECTRON EMITTING HIGH ENERGY LINEAR ACCELERATORS BY REGION, THROUGH 2019 (\$ MILLIONS)	43
TABLE 10 LINACS MARKET BY TECHNIQUES, THROUGH 2019 (\$ MILLIONS)	43
TABLE 11 THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY BY REGION, THROUGH 2019 (\$ MILLIONS)	44
TABLE 12 INTENSITY-MODULATED RADIATION THERAPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	46
TABLE 13 IMAGE-GUIDED RADIATION THERAPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	47
TABLE 14 OTHER LINACS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	48
TABLE 15 COMPARISON OF PROTON BEAM THERAPY AND CARBON ION THERAPY	50
TABLE 16 PARTICLE THERAPY SYSTEM BY TYPE, THROUGH 2019 (\$ MILLIONS)	51
TABLE 17 PARTICLE THERAPY SYSTEM MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	51
TABLE 18 PROTON SYSTEMS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	52
TABLE 19 CARBON ION THERAPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	52
TABLE 20 COMMONLY USED RADIONUCLIDES (RADIATION SOURCES) FOR BRACHYTHERAPY	54
TABLE 21 ADVANTAGES AND DISADVANTAGES OF BRACHYTHERAPY	54
TABLE 22 VARIOUS TYPES OF BRACHYTHERAPY IMPLANTS	55
TABLE 23 BRACHYTHERAPY TREATMENT DURATION	55
TABLE 24 BRACHYTHERAPY TREATMENT DOSE RATE	56
TABLE 25 BRACHYTHERAPY TREATMENT SOURCE LOADING	56
TABLE 26 COMPARISON OF LOW DOSE AND HIGH DOSE RADIATION THERAPY	57
TABLE 27 GLOBAL BRACHYTHERAPY MARKET BY PRODUCT, THROUGH 2019 (\$ MILLIONS)	58
TABLE 28 GLOBAL BRACHYTHERAPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	58
TABLE 29 GLOBAL LDR BRACHYTHERAPY MARKET BY PRODUCT, THROUGH 2019 (\$ MILLIONS)	59
TABLE 30 GLOBAL LDR BRACHYTHERAPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	59
TABLE 31 MARKET FOR LDR BRACHYTHERAPY SEEDS BY REGION, THROUGH 2019 (\$ MILLIONS)	60
TABLE 32 GLOBAL BRACHYTHERAPY SEEDS MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	61

TABLE HEADING	PAGE NO.
TABLE 33 GLOBAL I-125 SEEDS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	62
TABLE 34 GLOBAL PD-103 SEEDS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	62
TABLE 35 GLOBAL OTHER LDR BRACHYTHERAPY SEEDS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	63
TABLE 36 LDR AFTERLOADER AND APPLICATOR MARKET BY GEOGRAPHY THROUGH 2019 (\$ MILLIONS)	63
TABLE 37 HDR BRACHYTHERAPY MARKET BY PRODUCT, THROUGH 2019 (\$ MILLIONS)	65
TABLE 38 HDR BRACHYTHERAPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	65
TABLE 39 HDR SEEDS MARKET BY PRODUCT, THROUGH 2019 (\$ MILLIONS)	67
TABLE 40 HDR SEEDS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	67
TABLE 41 IR-192 SEEDS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	68
TABLE 42 OTHER HDR SEEDS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	69
TABLE 43 HDR AFTERLOADER AND APPLICATOR MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	69
TABLE 44 COMPARISON BETWEEN RADIONUCLIDES AND ELECTRONIC BRACHYTHERAPY	71
TABLE 45 GLOBAL ELECTRONIC BRACHYTHERAPY MARKET BY GEOGRAPHY THROUGH 2019 (\$ MILLIONS)	71
TABLE 46 ADVANTAGES AND DISADVANTAGES OF RADIOPHARMACEUTICALS	72
TABLE 47 COMPARISON OF ALPHA AND BETA PARTICLES	73
TABLE 48 MARKET FOR THERAPEUTIC RADIOPHARMACEUTICALS BY TYPE, THROUGH 2019 (\$ MILLIONS)	74
TABLE 49 SYSTEMIC RADIATION THERAPY BY REGION, THROUGH 2019 (\$ MILLIONS)	74
TABLE 50 GLOBAL ALPHA EMITTER MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	75
TABLE 51 GLOBAL ALPHA EMITTER MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	75
TABLE 52 EXAMPLES OF ALPHA EMITTERS	77
TABLE 53 ADVANTAGES AND DISADVANTAGES OF ALPHA EMITTERS	77
TABLE 54 GLOBAL BETA EMITTERS MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	80
TABLE 55 ADVANTAGES AND DISADVANTAGES OF BETA EMITTERS	81
TABLE 56 MARKET FOR BETA EMITTERS BY REGION, THROUGH 2019 (\$ MILLIONS)	82
TABLE 57 GLOBAL IODINE-131 MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	83
TABLE 58 GLOBAL RHENIUM-186 MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	84
TABLE 59 GLOBAL SAMARIUM-153 MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	85
TABLE 60 GLOBAL YTTRIUM-90 MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	86
TABLE 61 GLOBAL LUTETIUM-177 MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	87
TABLE 62 GLOBAL OTHER BETA EMITTERS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	87
TABLE 63 OTHER ROUTES OF ADMINISTRATION	89
TABLE 64 PIPELINE PRODUCTS IN RADIOPHARMACEUTICALS	90
TABLE 65 EXTERNAL BEAM RADIATION THERAPY BY APPLICATION, THROUGH 2019 (\$ MILLIONS)	93
TABLE 66 INTERNAL BEAM RADIATION THERAPY BY APPLICATION THROUGH 2019 (\$ MILLIONS)	101
TABLE 67 SYSTEMIC RADIATION THERAPY BY APPLICATION, THROUGH 2019 (\$ MILLIONS)	105
TABLE 68 U.S. RADIATION THERAPY MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	109
TABLE 69 U.S. INSTALLED BASE AND AGE	109
TABLE 70 NEW CANCER CASES AND ESTIMATED DEATHS IN THE YEAR 2014	110

TABLE HEADING	PAGE NO.
TABLE 71 AGING U.S. POPULATION, 2000-2050	110
TABLE 72 EUROPEAN RADIATION THERAPY MARKET BY TYPE THROUGH 2019 (\$ MILLIONS)	111
TABLE 73 ASIAN RADIATION THERAPY MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	112
TABLE 74 COMPARISON OF INDIAN AND CHINESE RADIATION THERAPY MARKETS	113
TABLE 75 REST OF THE WORLD RADIATION THERAPY MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	115
TABLE 76 ACCURAY REVENUES AND R &D EXPENDITURES, 2011-2013 (\$ MILLIONS/%)	117
TABLE 77 ACCURAY PRODUCTS	118
TABLE 78 ACCURAY RECENT NEWS	118
TABLE 79 C.R. BARD REVENUES AND R &D EXPENDITURES, 2011-2013 (\$ MILLIONS)	120
TABLE 80 ECKERT & ZIEGLER REVENUES AND R &D EXPENDITURES, 2011-2013 (\$ MILLIONS/%)	122
TABLE 81 ECKERT & ZIEGLER RECENT NEWS	122
TABLE 82 ELEKTA REVENUES AND R &D EXPENDITURES, 2011-2013 (\$ MILLIONS/%)	124
TABLE 83 ELEKTA RECENT NEWS	125
TABLE 84 SIEMENS REVENUES AND R &D EXPENDITURES, 2011-2013 (\$ MILLIONS/%)	129
TABLE 85 SIEMENS RECENT NEWS	129
TABLE 86 VARIAN REVENUES AND R &D EXPENDITURES, 2011-2013 (\$ MILLIONS/%)	131
TABLE 87 VARIAN RECENT NEWS	131
TABLE 88 LIST OF CARCINOGENIC AGENTS	135

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE RADIATION THERAPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	8
FIGURE 1 TYPES OF RADIATION	14
FIGURE 2 CELL GROWTH CYCLE	19
FIGURE 3 RADIATION THERAPY MARKET SEGMENTATION	22
FIGURE 4 DRIVERS, RESTRAINTS, OPPORTUNITIES AND TRENDS IN THE RADIATION THERAPY MARKET	23
FIGURE 5 GLOBAL AGING POPULATION (MILLIONS)	24
FIGURE 6 FACTORS RELATED TO AGING AND THE PROMOTION OF CANCER	25
FIGURE 7 MARKET SHARE ANALYSIS OF THE RADIATION THERAPY MARKET, 2013 (%)	30